Name: Glycyl Tyrosine
Brand: Creative Peptides
SKU: CPC1663
Availability: MadeToOrder

M.F/Formula

C11H14N2O4

M.W/Mr.

238.24

Functions

Glycyltyrosine is a dipeptide composed of glycine and tyrosine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

Mechanism of Action (MOA)

Glycyl Tyrosine is a dipeptide composed of glycine and tyrosine. Upon topical application, it may interact with skin cells by supporting cellular communication pathways involved in protein synthesis and metabolic regulation. The tyrosine residue can serve as a substrate in enzymatic processes related to skin homeostasis, while glycine contributes to cellular matrix dynamics. This dipeptide is suitable for formulations targeting the maintenance of healthy-looking skin.

Glycyl Tyrosine can be incorporated into a variety of cosmetic formulations for targeted skin care solutions.

- Suitable for use in facial serums and creams
- Can be added to eye contour products
- Compatible with gel-based and emulsion systems
- Appropriate for leave-on and rinse-off applications
- May be included in formulations for sensitive skin types
- Recommended usage levels: 0.1–2%, as per formulation needs

1. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

2. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

3. Exosomes-mediated Transfer of miR-125a/b in Cell-to-cell Communication: A Novel Mechanism of Genetic Exchange in the Intestinal Microenvironment

4. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum

5. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients